Discovery of the first potent and orally available agonist of the orphan G-protein-coupled receptor 52

Journal of Medicinal Chemistry

Volumn 57, Issue 12, 2014, Pages 5226-5237

  Setoh, Masaki ^a   Ishii, Naoki ^a   Kono, Mitsunori ^a   Miyanohana, Yuhei ^a   Shiraishi, Eri ^a   Harasawa, Toshiya ^a   Ota, Hiroyuki ^a   Odani, Tomoyuki ^a   Kanzaki, Naoyuki ^a   Aoyama, Kazunobu ^a   Hamada, Teruki ^a   Kori, Masakuni ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 (3 CHLORO 5 FLUOROBENZYL) 1 BENZOTHIOPHEN 7 YL] N (2 METHOXYETHYL)BENZAMIDE; BENZOTHIOPHENE DERIVATIVE; CYCLIC AMP; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 52; G PROTEIN COUPLED RECEPTOR 52 AGONIST; HALOPERIDOL; METHAMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; ORPHAN NUCLEAR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN; CHO CELL LINE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CONFORMATION; DRUG PENETRATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; EXPERIMENTAL CATALEPSY; EXPERIMENTAL HYPERACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; MALE; MASS SPECTROMETRY; MOUSE; NEUROPHARMACOLOGY; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZAMIDES; BRAIN; CHO CELLS; CRICETULUS; HUMANS; MALE; METHAMPHETAMINE; MICE, INBRED ICR; MODELS, MOLECULAR; MOTOR ACTIVITY; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES;

EID: 84903512804     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5002919     Document Type: Article

References (17)

1. First, M. B.; Tasman, A. DSM-IV-TR Mental Disorders: Diagnosis, Etology and Treatment; Wiley: Chichester, U.K., 2004, pp 639-701.
2. Saha, S.; Chant, D.; Welham, J.; McGrath, J. A systematic review of the prevalence of schizophrenia PLoS Med. 2005, 2, e141
3. Thaker, G. K.; Carpenter, W. T., Jr. Advances in schizophrenia Nat. Med. 2001, 7, 667-671
4. Leucht, S.; Wahlbeck, K.; Hamann, J.; Kissling, W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis Lancet 2003, 361, 1581-1589
5. Newcomer, J. W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review CNS Drugs 2005, 19 (Suppl. 1) 1-93
6. Casey, D. E. Metabolic issues and cardiovascular disease in patients with psychiatric disorders Am. J. Med. 2005, 118 (Suppl. 2) 15S-22S
7. Taylor, D. M. Antipsychotics and QT prolongation Acta Psychiatr. Scand. 2003, 107, 85-95
8. Sawzdargo, M.; Nguyen, T.; Lee, D. K.; Lynch, K. R.; Cheng, R.; Heng, H. H. Q.; George, S. R.; O'Dowd, B. F. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, ψGPR53 and GPR55: GPR55 is extensively expressed in human brain Mol. Brain Res. 1999, 64, 193-198
9. Komatsu, H.; Maruyama, M.; Yao, S.; Shinohara, T.; Sakuma, K.; Imaichi, S.; Chikatsu, T.; Kuniyeda, K.; Foo, K. S.; Lam, S. P.; Zhuo, K.; Lay, S. M.; Tan, M.; Matsumoto, Y.; Hashimoto, T.; Miyajima, N.; Ito, Y.; Ogi, K.; Habata, Y.; Mori, M. Anatomical transcriptome of G protein-coupled receptors leads to the identification of a novel therapeutic candidate GPR52 for psychiatric disorders PLoS One 2014, 9, e90134
10. Setoh, M.; Kobayashi, T.; Tanaka, T.; Baba, A. Compound having 6-membered aromatic ring. WO 2009/107391, 2009.
11. Molecular Operating Environment, version 2010.10; Chemical Computing Group, Inc.: Montreal, Quebec, Canada, 2010.
12. Stewart, J. J. P. Optimization of parameters for semiempirical methods II. Applications J. Comput. Chem. 1989, 10, 209-220
13. Lau, C. K.; Belanger, P. C.; Dufresne, C.; Scheigetz, J.; Thtrien, M.; Fitzsimmons, B.; Young, R. N.; Ford-Hutchinson, A. W.; Riendeau, D.; Denis, D.; Guay, J.; Charleson, S.; Piechuta, H.; McFarlane, C. S.; Chiu, S-H. L.; Eline, D.; Alvaro, R. F.; Miwa, G.; Walsh, J. L. Development of 2,3-dihydro-6-(3- phenoxypropyl)-2-(2-phenylethyl)-5-benzofuranol (L-670,630) as a potent and orally active inhibitor of 5-lipoxygenase J. Med. Chem. 1992, 35, 1299-1318
14. Stille, J. R.; Ward, J. A.; Leffelman, C.; Sullivan, K. A. 5-Formylsalicylaldehyde as a linker for the synthesis of benzofuran containing insulin sensitivity enhancer compounds Tetrahedron Lett. 1996, 37, 9267-9270
15. King, L. C.; Ostrum, K. O. Selective bromination with copper(II) bromide J. Org. Chem. 1964, 29, 3459-3461
16. Agejas-Chicharro, J.; Bueno Melendo, A. B.; Camp, N. P.; Gilmore, J.; Jimenez-Aguado, A. M.; Lamas-Peteira, C.; Marcos-Llorente, A.; Mazanetz, M. P.; Montero Salgado, C.; Timms, G. H.; Williams, A. C. Pharmaceutical compounds. US 2004/122001, 2004.
17. Suzuki, Y.; Funakoshi, T.; Chaki, S.; Kawashima, N.; Ogawa, S.; Kumagai, T.; Nakazato, A.; Komurasaki, T.; Okuyama, S. In vitro and in vivo pharmacological profile of 4-(4-fluorobenzylidene)-1-[2-[5-(4-fluorophenyl)-1 H -pyrazol-4-yl] ethyl] piperidine (NRA0161) Life Sci. 2002, 71, 2603-2615